Melane Sampson, Author at BioTuesdays

Markets

BTIG starts Aerovate Therapeutics at buy; PT $24

BTIG launched coverage of Aerovate Therapeutics (NASDAQ:AVTE) with a “buy” rating and $24 price target. The stock closed at $9.40 on Feb. 10. Aerovate is focused exclusively on developing a dry powder inhaled...

February 11, 2022

Developments

Altamira Therapeutics, Wellesta expand Bentrio marketing, distribution

Altamira Therapeutics (NASDAQ:CYTO) expanded its existing marketing and distribution agreement with Wellesta Holding of Singapore for Altamira’s Bentrio nasal spray for personal protection against airborne viruses and...

February 9, 2022

Developments

Altamira Therapeutics, Avernus Pharma collaborate to distribute Bentrio in Gulf countries

Altamira Therapeutics (NASDAQ:CYTO) entered into an agreement with Avernus Pharma of Dubai for the marketing and distribution of Bentrio, Altamira’s nasal spray for protection against airborne viruses and...

February 7, 2022

Developments

Altamira Therapeutics establishes OTC Consumer Health business unit

Altamira Therapeutics (NASDAQ:CYTO) established a new business unit, OTC Consumer Health, to support the ongoing global roll out of Bentrio, its nasal spray for the protection against airborne viruses and allergens. OTC...

February 4, 2022

Developments

Talkiatry completes $37-million Series A financing

Closely held Talkiatry, a provider of in-network psychiatric care, completed its $37-million Series A financing with an additional $17-million from Left Lane Capital. The latest round of funding comes just five months...

January 27, 2022

Developments

Hepion’s rencofilstat combined with an immune checkpoint inhibitor demonstrates synergistic anti-tumor activity in a non-clinical liver cancer study

Results of a non-clinical research study demonstrated that Hepion Pharmaceuticals’ (NASDAQ:HEPA) clinical phase drug candidate, rencofilstat (CRV431), synergistically decreased liver tumor growth and extended mouse...

January 26, 2022

Developments

ENDRA partnering study of TAEUS with Shanghai General Hospital

ENDRA Life Sciences (NASDAQ:NDRA) received Institutional Review Board approval from China’s Shanghai General Hospital for the first clinical study, expected to begin in 2022, of ENDRA’s Thermo Acoustic Enhanced...

January 24, 2022

Developments

Dyadic introduces novel method to produce synthetic cannabinoids

Dyadic International (NASDAQ:DYAI) has engineered its C1-cell protein production platform to demonstrate the potential of manufacturing therapeutically viable and commercially useful cannabis compounds, including...

January 21, 2022

Developments

University of Cambridge begins COVID-19 trial with PharmaJet needle-free system

PharmaJet’s needle-free Injection system will be used in a clinical trial to deliver a booster vaccine against COVID-19 virus variants. The vaccine developed by DIOSynVax, a spinoff company supported by the University...

January 18, 2022

Executive Moves

Altamira updates RNA therapeutics program with new CDO, NIH grant

Altamira Therapeutics (NASDAQ:CYTO), in a business update on its development activities in RNA therapeutics, appointed Covadonga Pañeda, Ph.D., as chief development officer for RNA therapeutics, effective in early April...

January 13, 2022

Author - Melane Sampson

BTIG starts Aerovate Therapeutics at buy; PT $24

Altamira Therapeutics, Wellesta expand Bentrio marketing, distribution

Altamira Therapeutics, Avernus Pharma collaborate to distribute Bentrio in Gulf countries

Altamira Therapeutics establishes OTC Consumer Health business unit

Talkiatry completes $37-million Series A financing

Hepion’s rencofilstat combined with an immune checkpoint inhibitor demonstrates synergistic anti-tumor activity in a non-clinical liver cancer study

ENDRA partnering study of TAEUS with Shanghai General Hospital

Dyadic introduces novel method to produce synthetic cannabinoids

University of Cambridge begins COVID-19 trial with PharmaJet needle-free system

Altamira updates RNA therapeutics program with new CDO, NIH grant

Subscribe